Literature DB >> 24873727

C9orf72; abnormal RNA expression is the key.

Peter Heutink1, Iris E Jansen2, Emily M Lynes3.   

Abstract

An expanded GGGGCC hexanucleotide repeat in the first intron located between the 1st and 2nd non-coding exons of C9orf72 is the most frequent cause of frontotemporal dementia (FTD) and amyothropic lateral sclerosis (ALS). C9orf72 is a protein with largely unknown function and insight into the disease mechanism caused by the repeat expansion is still in an early stage but increases at an amazing pace. Three main hypotheses are currently being considered to explain the disease process including haploinsuffiency due to the loss of expression from the mutated allele, RNA toxicity caused by accumulation of repeat containing transcripts and toxic protein species generated by the abnormal translation of repeat sequences. We review the current status of genetic, population and functional data and discuss the current insights into the biology of C9orf72 and this repeat expansion disease.
Copyright © 2014 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24873727     DOI: 10.1016/j.expneurol.2014.05.020

Source DB:  PubMed          Journal:  Exp Neurol        ISSN: 0014-4886            Impact factor:   5.330


  6 in total

1.  Special Issue on amyotrophic lateral sclerosis.

Authors:  Bryan J Traynor; Don W Cleveland
Journal:  Exp Neurol       Date:  2014-08-23       Impact factor: 5.330

Review 2.  Transplantation of stem cell-derived astrocytes for the treatment of amyotrophic lateral sclerosis and spinal cord injury.

Authors:  Charles Nicaise; Dinko Mitrecic; Aditi Falnikar; Angelo C Lepore
Journal:  World J Stem Cells       Date:  2015-03-26       Impact factor: 5.326

3.  Aldehyde Dehydrogenases 1A2 Expression and Distribution are Potentially Associated with Neuron Death in Spinal Cord of Tg(SOD1*G93A)1Gur Mice.

Authors:  Huiting Liang; Chengsi Wu; Youqing Deng; Lei Zhu; Jie Zhang; Weiming Gan; Chunyan Tang; Renshi Xu
Journal:  Int J Biol Sci       Date:  2017-04-10       Impact factor: 6.580

4.  Targeting RNA-Mediated Toxicity in C9orf72 ALS and/or FTD by RNAi-Based Gene Therapy.

Authors:  Raygene Martier; Jolanda M Liefhebber; Ana García-Osta; Jana Miniarikova; Mar Cuadrado-Tejedor; Maria Espelosin; Susana Ursua; Harald Petry; Sander J van Deventer; Melvin M Evers; Pavlina Konstantinova
Journal:  Mol Ther Nucleic Acids       Date:  2019-02-11

5.  C9orf72 is differentially expressed in the central nervous system and myeloid cells and consistently reduced in C9orf72, MAPT and GRN mutation carriers.

Authors:  Patrizia Rizzu; Cornelis Blauwendraat; Sasja Heetveld; Emily M Lynes; Melissa Castillo-Lizardo; Ashutosh Dhingra; Elwira Pyz; Markus Hobert; Matthis Synofzik; Javier Simón-Sánchez; Margherita Francescatto; Peter Heutink
Journal:  Acta Neuropathol Commun       Date:  2016-04-14       Impact factor: 7.801

6.  Modifiers of solid RNP granules control normal RNP dynamics and mRNA activity in early development.

Authors:  Arnaud Hubstenberger; Cristiana Cameron; Scott L Noble; Sean Keenan; Thomas C Evans
Journal:  J Cell Biol       Date:  2015-11-02       Impact factor: 10.539

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.